A Randomized, Combined SAD/MAD Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of AST 008 in Healthy Subjects

Trial Profile

A Randomized, Combined SAD/MAD Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of AST 008 in Healthy Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs AST 008 (Primary)
  • Indications Atopic dermatitis; Brain cancer; Cancer; Epidermolysis bullosa; Eye-Disorders; Fibrosis; Gastrointestinal disorders; Inflammation; Lymphoma; Respiration disorders; Skin disorders; Solid tumours; Transplant rejection
  • Focus Adverse reactions
  • Sponsors Exicure
  • Most Recent Events

    • 14 Nov 2017 According to a Exicure media release, the company received authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) to conduct this trial in UK.
    • 16 Oct 2017 Planned End Date changed from 1 Apr 2018 to 31 Aug 2018.
    • 16 Oct 2017 Planned primary completion date changed from 28 Feb 2018 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top